Evidence map›Paper›PMID 32984037›Full record

ArticleFrontiers in oncology2020

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia.

Shanshan Guo, Bixia Li, Ying Chen, Duobing Zou, Shujun Yang, Yi Zhang, Ningning Wu, Lixia Sheng, He Huang, Guifang Ouyang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Mechanisms of circular RNA degradation.Communications biology · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Shanshan GuoNingbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Bixia LiSchool of Medicine, Ningbo University, Ningbo, China.
Ying ChenLaboratory of Stem Cell Transplantation, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Duobing ZouLaboratory of Stem Cell Transplantation, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Shujun YangDepartment of Hematology, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Yi ZhangLaboratory of Stem Cell Transplantation, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Ningning WuLaboratory of Stem Cell Transplantation, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Lixia ShengDepartment of Hematology, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
He HuangBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Guifang OuyangDepartment of Hematology, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Qitian MuLaboratory of Stem Cell Transplantation, Ningbo Hospital, School of Medicine, Zhejiang University, Ningbo, China.
Ningbo University · CNZhejiang University · CNNingbo No. 2 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemia (AL) is a group of highly heterogeneous hematological malignancies. Circular RNAs (circRNAs) are covalently closed circRNA molecules implicated in the development of many diseases. However, the role of circRNAs in AL remains largely unknown. Therefore, this study aimed to identify new classification diagnostic biomarkers for subgroups of AL. The circRNA expression signatures discriminating acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) were identified by microarray, followed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) validation. Receiver operating characteristic curve analysis was used to evaluate the diagnostic efficiencies of hsa_circ_0001857 and hsa_circ_0012152, and hsa_circ_0012152 was selected for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. The results showed that the circRNA expression profiles, hsa_circ_0001857, and hsa_circ_0012152 could clearly discriminate ALL from AML. The target genes of hsa_circ_0012152 might be involved in biological processes, such as myeloid cell differentiation, covalent chromatin modification, histone modification, and rat sarcoma (Ras) protein signal transduction, and participate in pathways such as mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3'-kinase (PI3K)-Akt signaling pathway. Hsa_circ_0012152 might be involved in the initiation and development of AML through miR-491-5p/epidermal growth factor receptor (EGFR)/MAPK1 or miR-512-3p/EGFR/MAPK1 axis. Our results showed that circRNA expression profiles and specifically expressed circRNAs were promising classification biomarkers to designate AL into ALL or AML.

Indexed as

acute lymphoblastic leukemiaacute myeloid leukemiabioinformaticsbiomarkercircRNA

Identifiers

PMID32984037
PMCPMC7492294
OpenAlexW3082255852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.